---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-196489"
form_type: "8-K"
ticker: "WVE"
cik: "0001631574"
company_name: "Wave Life Sciences Ltd."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T10:58:13.848546+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Wave Life Sciences Q2 net loss $32.9M; positive HD data with up to 46% mHTT reduction; cash $154M into Q4 2025

## Summary
- Q2 net loss $32.9M vs $21.1M YoY; revenue $19.7M vs $22.1M; cash $154M, sufficient into Q4 2025.
- SELECT-HD: WVE-003 reduced mutant HTT up to 46%, statistically significant; slowing caudate atrophy; Takeda opt-in submitted.
- DMD: FORWARD-53 dystrophin data expected 3Q2024; WVE-N531 previously showed 53% exon skipping.
- AATD: RestorAATion-2 dosing initiated; proof-of-mechanism data expected 4Q2024.
- Obesity: WVE-007 FIH study expected Q1 2025; preclinical data at R&D Day Fall 2024.

## SEC filing metadata
- accession: 0001193125-24-196489
- form_type: 8-K
- ticker: WVE
- cik: 0001631574
- company_name: Wave Life Sciences Ltd.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1631574/000119312524196489/0001193125-24-196489-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1631574/000119312524196489/d875535d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-196489
- JSON: https://secwatch.observer/filing/0001193125-24-196489.json
- Plain text: https://secwatch.observer/filing/0001193125-24-196489.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.